URGN•benzinga•
UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug
Summary
Analyst Selvaraju downgrades UroGen after FDA panel setback dims approval prospects for key bladder cancer drug UGN-102.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 25, 2025 by benzinga